| Policies for use of real-world data in health technology assessment (HTA): a comparative study of six HTA agencies A Makady, R Ten Ham, A de Boer, H Hillege, O Klungel, W Goettsch Value in Health 20 (4), 520-532, 2017 | 187 | 2017 |
| Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma MW Rohaan, TH Borch, JH Van Den Berg, Ö Met, R Kessels, ... New England journal of medicine 387 (23), 2113-2125, 2022 | 158 | 2022 |
| Challenges in advanced therapy medicinal product development: a survey among companies in Europe RMT Ten Ham, J Hoekman, AM Hövels, AW Broekmans, HGM Leufkens, ... Molecular Therapy-Methods & Clinical Development 11, 121-130, 2018 | 105 | 2018 |
| What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings RMT Ten Ham, AM Hövels, J Hoekman, GWJ Frederix, HGM Leufkens, ... Cytotherapy 22 (7), 388-397, 2020 | 40 | 2020 |
| Targeted Therapies Compared to Dacarbazine for Treatment of BRAFV600E Metastatic Melanoma: A Cost-Effectiveness Analysis V Shih, RM Ten Ham, CT Bui, DN Tran, J Ting, L Wilson Journal of skin cancer 2015, 2015 | 31 | 2015 |
| A review of methodological considerations for economic evaluations of gene therapies and their application in literature RMT Ten Ham, OH Klungel, HGM Leufkens, GWJ Frederix Value in Health 23 (9), 1268-1280, 2020 | 18 | 2020 |
| Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen M Van Nuland, RA Vreman, RMT Ten Ham, AHM de Vries Schultink, ... Breast cancer research and treatment 172, 143-150, 2018 | 17 | 2018 |
| Estimation of manufacturing development costs of cell-based therapies: a feasibility study RMT Ten Ham, JC Nievaart, J Hoekman, RS Cooper, GWJ Frederix, ... Cytotherapy 23 (8), 730-739, 2021 | 16 | 2021 |
| Use of social media in the assessment of relative effectiveness: explorative review with examples from oncology RRJ Kalf, A Makady, RM Ten Ham, K Meijboom, WG Goettsch, ... JMIR cancer 4 (1), e7952, 2018 | 13 | 2018 |
| Key considerations in the health technology assessment of advanced therapy medicinal products in Scotland, The Netherlands, and England RMT Ten Ham, GWJ Frederix, O Wu, W Goettsch, HGM Leufkens, ... Value in Health 25 (3), 390-399, 2022 | 11 | 2022 |
| Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma FW Thielen, RJSD Heine, S van den Berg, RMT Ten Ham, ... Cytotherapy 24 (12), 1245-1258, 2022 | 10 | 2022 |
| Modeling benefits, costs, and affordability of a novel gene therapy in hemophilia A RMT Ten Ham, SM Walker, MO Soares, GWJ Frederix, FWG Leebeek, ... HemaSphere 6 (2), e679, 2022 | 10 | 2022 |
| Understanding the major factors affecting response shift effects on health-related quality of life: what the then-test measures in a longitudinal prostate cancer registry RMT Ten Ham, JM Broering, MR Cooperberg, P Carroll, LS Wilson Clinical Genitourinary Cancer 18 (1), e21-e27, 2020 | 10 | 2020 |
| IMI-GetReal Workpackage 1 RR Kalf, A Makady, RM Ten Ham, K Meijboom, WG Goettsch Use of social media in the assessment of relative effectiveness: explorative …, 2018 | 10 | 2018 |
| Development and regulation of gene and cell-based therapies in Europe: a quantification and reflection RMT Ten Ham, AM Hövels, OH Klungel, HGM Leufkens, AW Broekmans, ... Trends in Pharmacological Sciences 41 (2), 67-71, 2020 | 8 | 2020 |
| Robust health utility assessment among long-term survivors of prostate cancer: results from the cancer of the prostate strategic urologic research endeavor registry CW Jeong, JE Cowan, JM Broering, RMT Ten Ham, LS Wilson, PR Carroll, ... European Urology 76 (6), 743-751, 2019 | 6 | 2019 |
| Cost-effectiveness assessment of monitoring abiraterone levels in metastatic castration-resistant prostate cancer patients RMT Ten Ham, M van Nuland, RA Vreman, LG de Graaf, H Rosing, ... Value in Health 24 (1), 121-128, 2021 | 5 | 2021 |
| Toward Transplantation of Liver Organoids: From Biology and Ethics to Cost-effective Therapy MJM Ten Dam, GWJ Frederix, RMT Ten Ham, LJW van der Laan, ... Transplantation 107 (8), 1706-1717, 2023 | 4 | 2023 |
| Renske Ten Ham, Anthonius de Boer, Hans Hillege, Olaf Klungel, & Wim Goettsch. 2017.‘Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative … A Makady Value in Health: The Journal of the International Society for …, 0 | 4 | |
| Increasing the information provided by probabilistic sensitivity analysis: The relative density plot JW Geenen, RA Vreman, C Boersma, OH Klungel, AM Hövels, ... Cost Effectiveness and Resource Allocation 18, 1-10, 2020 | 2 | 2020 |
W. GoettschVerified email at zinl.nl
